Clinical Trial Update: Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo [Phase 2]

View source ↗

Summary

Phase 2 trial assessing combined narrow-band UVB phototherapy and apremilast for vitiligo has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Vitiligo | Phase 2 | Status: COMPLETED